Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 2, 2012, Pages 248-257

  Borowitz, Drucy ^a   Stevens, Christopher ^b   Brettman, Lee R ^b   Campion, Marilyn ^b   Wilschanski, Michael ^c   Thompson, Henry ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b Alnara Pharmaceuticals   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d St Lukes Childrens Hospital   (United States)

Author keywords

cystic fibrosis; malabsorption; nutritional status; pancreatic enzymes; pancreatic insufficiency

Indexed keywords

LIPROTAMASE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; ENZYME REPLACEMENT; FEMALE; FLATULENCE; FORCED EXPIRATORY VOLUME; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE OBSTRUCTION; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; OPEN STUDY; PANCREAS EXOCRINE INSUFFICIENCY; PANCREATIC ENZYME REPLACEMENT THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SIDE EFFECT; STEATORRHEA; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AMYLASES; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; LIPASE; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; PEPTIDE HYDROLASES; TREATMENT OUTCOME; YOUNG ADULT;

SUS;

EID: 84856260387     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31823315d1     Document Type: Article

References (37)

1. Borowitz D, Baker SS, Duffy L, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145:322-6. (Pubitemid 39165679)
2. Shwachman H. Therapy of cystic fibrosis of the pancreas. Pediatrics 1960;25:155-63.
3. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
4. Cherney B. Viral safety issues for the pancreatic enzyme product CREON. http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4402s1-02-FDA-Cherney%20.pdf. Accessed May 1, 2011.
5. Smyth RL, van Velzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343:85-6. (Pubitemid 24019350)
6. Freiman JP, FitzSimmons SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. J Pediatr Gastroenterol Nutr 1996;22:153-6. (Pubitemid 26065986)
7. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283-9. (Pubitemid 27187781)
8. Borowitz DS, Grand RJ, Durie PR. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. Consensus Committee. J Pediatr 1995;127:681-4.
9. Borowitz D, Parad RB, Sharp JK, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009; 155:S106-16.
10. The United States Pharmacopeia, 32nd rev, and the National Formulary, 27th ed. Rockville, MD: United States Pharmacopeial Convention 2009 3194-8
11. Whitehead AM. Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations. Pharm Weekbl Sci 1988;10:12-6. (Pubitemid 18056138)
12. Kraisinger M, Hochhaus G, Stecenko A, et al. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994; 34:158-66. (Pubitemid 24079922)
13. O'Hare MM, McMaster C, Dodge JA. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J Pediatr Gastroenterol Nutr 1995;21:59-63.
14. Kuhn R, Eyting S, Henniges F, et al. In vitro comparison of physical parameters, enzyme activity, acid resistance and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther 2007;12:115-28.
15. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995;346:1247-51.
16. Hendeles L, Dorf A, Stecenko A, et al. Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. JAMA 1990;263:2459-61. (Pubitemid 20169457)
17. Hendeles L, Hochhaus G, Kazerounian S. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Am J Hosp Pharm 1993;50:323-9. (Pubitemid 23051955)
18. Food and Drug Administration. Exocrine Pancreatic Insufficiency Drug Products for Over-the-Counter Human Use (Final Rule). Federal Register [final rule]. 1995;60:20162-5.
19. Food and Drug Administration. Exocrine Pancreatic Insufficiency Drug Products (Notice). Federal Register [notice]. 2004;69:23410-4.
20. Food and Drug Administration. Exocrine Pancreatic Insufficiency Drug Products: Extension to Obtain Marketing Approval (Notice). Federal Register 2007;72:60860-2.
21. Kermanshahi H, Maenz DD, Classen HL. Stability of porcine and microbial lipases to conditions that approximate the small intestine of young birds. Poult Sci 1998;77:1671-7. (Pubitemid 128528858)
22. Raimondo M, DiMagno EP. Lipolytic activity of bacterial lipase survives better than that of porcine lipase in human gastric and duodenal content. Gastroenterology 1994;107:231-5. (Pubitemid 24195366)
23. Basu SK, Govardhan CP, JungCW, et al. Protein crystals for the delivery of biopharmaceuticals. Expert Opin Biol Ther 2004;4:301-17. (Pubitemid 38352127)
24. Shenoy B, Wang Y, Shan W, et al. Stability of crystalline proteins. Biotechnol Bioeng 2001;73:358-69. (Pubitemid 32493232)
25. Borowitz D, Goss CH, Stevens C, et al. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. Pancreas 2006;32:258-63.
26. Borowitz D, Goss CH, Limauro S, et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 2006;149:658-62.
27. Borowitz D, Stevens C, Brettman L, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros 2011 [e-pub Aug 9].
28. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-20. (Pubitemid 39245114)
29. Cystic Fibrosis Foundation Patient Registry, 2008 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation.
30. Borowitz D, Stevens C, Campion M, et al. Relationship of baseline and treatment coefficient of fat absorption to growth in patients with cystic fibrosis (abstract). Pediatr Pulmonol 2010;45(33 suppl):424.
31. van der Doef HPJ, Kokke FTM, Beek FJA, et al. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibr 2010;9:59-63.
32. Dray X, Desmazes-Dufeu N, Dusser D, et al. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004;2:498-503. (Pubitemid 38698366)
33. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5:177-85. (Pubitemid 44063951)
34. Fuhrman MP. The albumin-nutrition connection: separating myth from fact. Nutrition 2002;18:199-200. (Pubitemid 34158684)
35. Shenkin A. Serum prealbumin: is it a marker of nutritional status or of risk of malnutrition? Clin Chem 2006;52:2177-9. (Pubitemid 44924987)
36. Peretti N, Marcil V, Drouin E, et al. Mechanisms of lipid malabsorption in cystic fibrosis: the impact of essential fatty acids deficiency. Nutr Metab (Lond) 2005;2:11.
37. Stallings VA, Stark LJ, Robinson KA, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008;108:832-9. (Pubitemid 351602057)